Earlier this week, The Washington Post falsely claimed that the PhRMA supported the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 and spent $40 million advocating for its enactment. As stated previously, these claims are unequivocally false and last night The Washington Post issued a correction clarifying that PhRMA did not take a position on the legislation.
Recently, PhRMA has taken a number of steps to address the opioid crisis, such as announcing its support for a 7-day script limit on opioids for acute pain and launching a new partnership with the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA) to bring new non-opioid therapies to market for patients who need them.
We will continue to work with other stakeholders to fight this terrible epidemic.
Holly Campbell
Holly Campbell is former deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines.
Holly Campbell
More oversight needed of unapproved medicines that threaten patients’ health
Florida’s importation plan puts patients in danger
Three things to know about the accelerated approval pathway
Why drug importation is bad for Americans
The Washington Post retracts PhRMA claim in opioid story
Rx Drug Abuse
Prescription Drug Safety
The Washington Post retracts PhRMA claim in opioid story
The Washington Post retracts PhRMA claim in opioid story